...
ARDXSMALL

Ardelyx, Inc.

HealthcareBiotechnology
$6.55
$0.00(-1.21%)
52W$3.21
$8.40
FinancialsValuationvs UTHR
Updated Mar 1, 12:00 AM
RSI46
RS Rating82/99
Beta0.62
Volatility70%
F-Score3/9
Mkt Cap$1.6B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Ardelyx, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings growth of 23% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.

Relative Strength
82
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.62
vs S&P 500
DEFENSIVE
52W Position
64%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$6.82
50 SMA > 100 SMA$6.19
100 SMA > 150 SMA$6.05
150 SMA > 200 SMA$5.54

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$6.94-5.63%BELOW
50 SMA$6.82-3.91%BELOW
100 SMA$6.19+5.90%ABOVE
150 SMA$6.05+8.24%ABOVE
200 SMA$5.54+18.29%ABOVE

Price Performance

1D-1.2%
1W+13.9%
1M-16.7%
3M+12.9%
6M+2.7%
YTD+6.5%
1Y+22.2%
3Y+31.5%
52-Week Trading Range64% from low
$6.55
52W Low$3.21
52W High$8.40

Technical Indicators

RSI (14)NEUTRAL
46.1
305070
VCP ScoreCOOL
4/10
Base depth: 43.8%

Risk Profile

Beta
0.62
52W Vol
70%
ATR
$0.38
Max DD (1Y)
-42%

Volume Analysis

Today
6
50D Avg
4.12M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+116%
$0.02
Q1'25-55%
$-0.17
Q2'25-13%
$-0.08
Q3'25-18%
$-0.00
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+32.72%
5 Years:+121.90%
3 Years:+98.40%
TTM:+58.12%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+22.73%

Stock Price CAGR

10 Years:+10.47%
5 Years:+30.66%
3 Years:+31.51%
1 Year:+22.20%

Return on Equity

10Y Avg:-64.3%
5Y Avg:-67.0%
3Y Avg:-36.4%
Last Year:-36.7%

Key Metrics

Market Cap$1.6B
Gross Margin90.3%
Net Margin-15.1%
Piotroski F-Score3/9

More ARDX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ARDX vs UTHRUTHRZLABAMRNALKS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 82 meansARDX outperformed 82% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.62 means 38% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is ARDX in an uptrend right now?

ARDX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ARDX overbought or oversold?

ARDX's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.

Is ARDX outperforming the market?

ARDX has a Relative Strength (RS) Rating of 82 out of 99. Yes, ARDX is a market leader, outperforming 82% of all stocks over the past 12 months.

Where is ARDX in its 52-week range?

ARDX is trading at $6.55, which is 78% of its 52-week high ($8.40) and 64% above its 52-week low ($3.21).

How volatile is ARDX?

ARDX has a Beta of 0.62 and 52-week volatility of 70%. It's less volatile than the S&P 500 - generally more stable.